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Background: Gynaecological cancers account forB12% of female cancer incidence in the United Kingdom. Encouraging prompt
help-seeking for potential symptoms could help improve outcomes. However, before developing help-seeking interventions, it is
important to estimate the number of women with symptoms potentially indicative of a gynaecological cancer to help estimate the
impact of such interventions on primary care.
Methods: As part of a face-to-face, population-based survey, women aged X16 (n¼ 911) were shown a list of symptoms
potentially indicative of a gynaecological cancer and were asked to indicate any experienced in the last 3 months. Those who
reported symptoms were asked about their responses to one randomly selected index symptom.
Results: Just under half (44%) of the respondents reported a symptom, with 35% reporting a frequent and/or severe symptom.
Younger (Po0.001), lower socioeconomic status (Po0.01) and non-White women (Po0.05) were significantly more likely to report
symptoms. Few (14%) respondents were both older (X45 years) and had a frequent and/or severe symptom. Of these women, 38%
had seen a GP.
Conclusion: Symptoms that potentially indicate a gynaecological cancer, even if limited to those that are frequent and/or severe,
appear to be common. Consequently, encouraging prompt help-seeking may increase the burden on primary care. However,
targeting those at increased risk (older women with frequent or severe symptoms) should avoid unmanageable increases in
primary care consultations for gynaecological conditions.
Gynaecological cancers (uterine, vaginal, cervical, ovarian and
vulval cancers) account for around 12% of new female cancer
diagnoses per year in the United Kingdom (UK); (Cancer Research
UK, 2012a, 2012b; Office for National Statistics, 2012a) equalling
lung cancer and second only to breast cancer diagnoses. One-year
survival rates have been argued to be a proxy for late-stage
diagnoses (Department of Health, 2007), and there is evidence that
1-year survival rates for gynaecological cancers are significantly
lower in England compared with other European countries (Sant
et al, 2009; Thomson and Forman, 2009). Recent data from the
International Cancer Benchmarking Partnership have also demon-
strated lower 1-year survival rates for some cancers (including
ovarian) in the UK compared with other countries with similar
cancer plans (Coleman et al, 2011).
Data on stage distribution could confirm the hypothesis that
these poorer 1-year survival rates are due to higher rates of late-
stage diagnoses. However, these data are not readily available for all
gynaecological cancers in the UK due to the general lack of
accurate recording of staging data (Department of Health, 2012).
For vaginal and vulval cancers, there are no UK figures on stage
distribution, probably due to the relative rarity of these cancers
compared with the other three (Cancer Research UK, 2013a).
Specific stage-distribution figures for uterine cancer in the UK are
also not immediately available, although most cases are diagnosed
in the early stages. This could be because of the appearance
of easily recognisable symptoms (i.e., post-menopausal bleeding)
early in disease progression (Amant et al, 2005). Despite this, given
that the difference in survival rate between early- and late-stage
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cancers is wide (85% for Stage 1 and 25% for Stage IV (Cancer
Research UK, 2013b)), it is argued that any increase in earlier
diagnoses may be beneficial.
For cervical cancer, the stage distribution favours early-stage
diagnosis, with 75% of women in the UK diagnosed at FIGO stage
I. This is likely to be attributable to the organised population-based
screening programme through which the majority of stage I
cervical cancers in women aged o49 years are diagnosed (NHS
Cancer Screening Programmes, 2012). However, around a quarter
of women (26%) in the highest incidence age group (30–39
(Cancer Research UK, 2013c)) are not up to date with screening
(Health & Social Care Information Centre, 2012), and the majority
of unscreened women in the age groups 20–34 and 35–49 are
diagnosed with a later stage of cervical cancer (FIGO stage IBþ )
(NHS Cancer Screening Programmes, 2012). As with uterine
cancer, given the differences in survival rates between early- and
late-stage cervical cancers (over 99% at stage Ia1 and 46% at stage
IVb) (Benedet et al, 2003), reducing the number of later-stage
diagnoses in unscreened women is likely to improve outcomes.
Recent data for ovarian cancer show that despite poorer 1-year
survival rates, the proportion of early-stage diagnoses in the UK is
comparable to other countries (Maringe et al, 2012). Therefore, it is
argued that the lower observed 1-year survival rates are more likely
to be a result of poorer management of the women diagnosed at
more advanced stages than higher numbers of late diagnoses.
Nevertheless, early diagnosis could still improve outcomes for
ovarian cancer. For example, the majority of high-grade serous
ovarian cancers (HGSCs) (which are included in type II epithelial
ovarian cancers; responsible for the majority of all ovarian cancer
mortality (Brown and Palmer, 2009)) originate outside the ovaries,
spreading to the ovaries as they progress (Gilbert et al, 2012). This
results in these tumours becoming advanced-stage early in their
development (Cho and Shih, 2009). For type II ovarian cancers,
prognosis is influenced by tumour volume, not stage (Kurman
et al, 2008), and moving the focus of early diagnosis for ovarian
cancer from early stage to detection of low-volume disease in type
II cancers, or early diagnosis of HGSCs, could substantially
improve outcomes (Gilbert et al, 2012).
There are currently no screening programmes for any
gynaecological cancers except cervical, although results of a large
randomised controlled trial testing population screening for
ovarian cancer are awaited (Menon et al, 2009). Meanwhile,
encouraging women with symptoms to consult their general
practitioner (GP) promptly is important, particularly, when
considering the proportions of women diagnosed with a gynaeco-
logical cancer through emergency presentation or by death
certificate only (30% of ovarian, 8% of uterine and 12% of cervical
cancer diagnoses (National Cancer Intelligence Network,
2010)). Encouragement to seek help could bring these groups into
primary care.
However, encouraging prompt symptom presentation and
increasing consultation rates might have a significant impact on
the primary care workload. Although there is some evidence on
which to base estimates of GP consultation levels for gynaecolo-
gical conditions (Stapley and Hamilton, 2011), it is likely that there
is a wider group of women with symptoms who do not currently
seek help from their GP. Although these symptoms are unlikely to
be cancer, encouraging help-seeking could not only increase earlier
cancer diagnoses but also aid in detection of other potentially
treatable conditions.
There has been some qualitative research in the United States
examining gynaecological cancer symptom awareness and
women’s responses to symptoms across all five of the cancer types
(Cooper et al, 2012) and some research in the UK exploring
symptom awareness for individual gynaecological cancers
(Low et al, 2012, 2013). However, to our knowledge, there have
been no assessments of the population prevalence of symptoms
encompassing all gynaecological cancers in UK women, nor have
the frequency or severity of symptoms or help-seeking responses
been investigated. It is important not only to identify symptoms
experienced and responses to these symptoms but also to consider
the frequency and severity of symptoms, as symptoms that are
frequent or severe are more likely to indicate a gynaecological
cancer (Olson et al, 2001; Goff et al, 2004). This is the first study to
assess the prevalence of symptoms potentially indicative of a
gynaecological cancer, as well the frequency and severity of
symptoms and current help-seeking behaviour in response to
symptoms.
MATERIALS AND METHODS
Recruitment. As part of their omnibus survey (which included
modules from different contributors, on a range of non-health
topics) we commissioned the market research agency, TNS Global
(www.tns-ri.co.uk, London), to approach 2173 women (age X16
years) using stratified random location sampling. Women were
invited to complete our survey module using Computer Assisted
Personal Interviewing (CAPI) in the presence of trained inter-
viewers in their own homes, in July 2011. Before deciding whether
to participate, potential respondents were given written informa-
tion about the study due to the sensitive nature of the questions.
The information explained that the survey contained questions
about bodily changes experienced in the last 3 months, including
changes in the reproductive system. It made clear that the module
was anonymous and confidential, and that respondents who
decided to take part were free to withdraw at any time. The
interview was conducted in English, and therefore any women who
were not fluent in English were excluded. The study was approved
by the UCL Research Ethics Committee (ref: 1122/005).
Measures
Demographics. Respondents were classified as having a higher or
lower socioeconomic status (SES) (A, B, C1 vs C2, D, E categories)
using the National Readership Survey social grading system
(National Readership Survey, 2007). Only 7% of respondents
reported minority ethnicities, so they were grouped together and
the sample was categorised as ‘White’ or ‘non-White’. We
dichotomised age at 45 years because 85% of all new cases of
gynaecological cancers in the UK are in women aged X45 years
(Cancer Research UK, 2012a, 2012b, 2013b, 2013c, 2013d).
Symptom reporting. Women were presented with a list of 13
symptoms (see Table 2), potentially indicative of a gynaecological
cancer (sourced from NHS Choices (NHS Choices, 2013)), and
asked, ‘In the past 3 months, have you experienced any of the
following [symptoms]? (please answer each item with ‘yes’, or ‘no’. If
you are not sure, or if the item does not apply to you, answer ‘no’)’.
A 3-month reporting time frame was selected as some symptoms
could only be detected following at least two menstrual cycles (e.g.,
inter-menstrual bleeding). In the analyses, it was not possible to
stratify symptoms by gynaecological cancer type as many of the
symptoms overlap.
Symptom frequency and severity. Respondents reporting a
symptom were asked, ‘Please tell us (as far as you remember)
how often you experienced [symptom] in the past 3 months’.
Response options included: ‘Once’, ‘twice’ (both recoded as
‘infrequent’), ‘several times’ and ‘all the time’ (both recoded as
‘frequent’). They were then asked: ‘Using the 5-point scale below,
please tell us how bad the [endorsed symptom] was on the worst day
you had it. If it was as bad as you could imagine it could be, score 5.
If it was not bad at all, score 1. Please remember you can score any
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number from 1 to 5’. Reponses were recoded into ‘not severe’
(scores 1–3) or ‘severe’ (score 4 or 5). The frequency and severity
questions were repeated for each symptom the respondent
reported. For some analyses, we divided respondents into two
groups: (i) with a symptom that was severe (score 4 or 5), frequent
(‘several times’ or ‘all the time’) or both and (ii) with a symptom
that was neither frequent nor severe. These questions were similar
to those used in other studies exploring frequency and severity of
symptoms potentially indicative of a cancer (e.g., Goff et al, 2004).
Help-seeking. To measure help-seeking, we asked, ‘Please tell us
from the following what, if anything, you did about your
[symptom]’. Response options included seeking advice from a
pharmacist (chemist); a practice nurse; a GP; going to A&E (the
hospital emergency department); asking for advice from a friend/
relative; looking for advice on the internet; asking/looking for
advice somewhere else; using an own remedy/treating it them-
selves; and waiting to see if it went away/got worse. For each
response option, respondents answered ‘Yes’ or ‘No’. Women were
only asked about help-seeking for one randomly system-selected
symptom, referred to here as the ‘index symptom’. The study was
designed in this way to avoid the survey becoming so time-
consuming that it would be off-putting to participants.
Analyses. Data were weighted by region, age and SES to achieve a
nationally representative female sample and were analysed using
SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) (SPSS, 2009). We
assessed demographic differences between survey responders and
non-responders using t-tests and w2 tests. We used w2 tests to
identify significant demographic differences in symptom reporting
and group differences in help-seeking behaviour.
RESULTS
Sample characteristics. Of the 2173 women who took part in the
overall TNS omnibus survey, 911 (42%) completed our survey
module. Respondents were aged 16–98, with a mean (M) age of 45
years. When age was dichotomised, 442 women were aged X45
years and 469 were aged o45 years. Most women were White
(93%), married/living as a couple (61%) and had a high SES (60%).
Responders to our survey module were significantly younger, had a
higher SES, were more likely to have a White ethnicity and were
more likely to be married or living as a couple than those who
refused to complete the module (see Table 1).
Symptom reporting. Just under half of the respondents (44%,
398/911) reported at least one of the 13 symptoms in our survey
(M¼ 1.2, range¼ 0–9), with ‘pain in the abdomen, lower back or
pelvis’ (19%, n¼ 173), ‘increased abdominal size’ (17%, n¼ 154)
and ‘increased need to go to the toilet’ (15%, n¼ 138) being the
most common (Table 2). The median number of symptoms
endorsed was 0 (n¼ 513, 56%), with 11% reporting one symptom
(n¼ 103), 12% reporting two symptoms (n¼ 108) and 21%
reporting three symptoms or more (n¼ 187). The highest number
of symptoms experienced was nine, reported by five women
(0.5%). Women were more likely to report a symptom indicative of
a gynaecological cancer if they were younger (50% of those under
45 vs 37% of those aged 45 and over, w2 (1, 910)¼ 14.87, Po0.001),
had a lower SES (49% vs 40% in the higher SES group, w2
(1, 911)¼ 7.58, Po0.01) and were non-White (58% vs 43% in
White participants, w2(1, 910)¼ 5.64, Po0.05).
Frequency and severity of symptoms. Overall, 35% (n¼ 317/911)
of respondents reported a symptom that was frequent and/or
severe, and 9% (78/911) had a symptom that was neither frequent
nor severe. Less than a third (132/442, 30%) of women aged X45
reported a frequent and/or severe symptom, 14% of the total
sample (n¼ 132/911) (Table 3). There were no significant
demographic differences between the two frequency/severity
groups. Individual symptom endorsements by age and frequency
and/or severity of symptom are reported in Table 2.
Help-seeking behaviour. Respondents were asked about help-
seeking for a single index symptom. The selection rate for each
symptom (expressed as the number of times the symptom was
selected as a proportion of the number of times that symptom was
endorsed) was fairly similar across symptoms (see Table 2). Just
over a third (36%, 142/398) of respondents who reported a
symptom had seen a health-care professional (HCP) (pharmacist,
GP, practice nurse, A&E) about their index symptom, with most
(30%, 120/398) having seen a GP. In symptomatic women, the
most common response to the index symptom was to monitor it
(54%, 216/398) and the least common response was to go to A&E
(6%, 24/398). In the sample as a whole, 16% (n¼ 142/911) of
women had seen an HCP about their index symptom and 13% had
seen a GP (n¼ 120/911).
Of the older (X45 years) symptomatic women, 37% (n¼ 60/
164) had seen an HCP and 33% (54/164) had seen a GP. The most
common response to a symptom was to monitor it (49%, 81/164)
and the least common response was to visit the A&E department
(2%, 4/164). Older women were significantly less likely to
have asked a friend or relative for advice (14% vs 28%,
w2 (1, 399)¼ 11.36, P¼ 0.001) or to have gone to A&E (2% vs 9%,
w2 (1, 398)¼ 6.47, Po0.05) than younger women. The behaviour
patterns remained the same for women with a frequent and severe
symptom, although more women had sought medical help, with
42% having seen an HCP (135/317).
Table 1. Sociodemographic characteristics of responders and non-
responders to the symptom survey module (weighted data, overall
n¼ 2173)
Responders
(n¼911)
n%
Non-
respondersa
(n¼1262)
n%
v2 (df)
Age (mean, (SD), t-test) 45 (17) 49 (20) 5.61b
Socioeconomic status
ABC1 (higher) 543 (60) 674 (53)
C2DE (lower) 368 (40) 588 (47) 8.25 (1)c
Ethnicity
White 848 (93) 1097 (88)
Non-white 62 (7) 154 (12) 17.69 (1)b
Marital status
Single 204 (22) 294 (23)
Widowed/divorced/
separated
149 (16) 283 (22)
Married/living as a couple 558 (61) 676 (54) 15.10 (2)b
Reported symptoms
At least one 398 (44) — —
None 513 (56) — —
aThese women took part in the omnibus survey but opted out of our symptom survey
module.
bsignificant at the 0.001 level.
cSignificant at the 0.01 level.
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Among the older women (X45 years) with an index symptom
that was frequent and/or severe (i.e., the most high-risk group),
43% (n¼ 56/132) had seen an HCP and 38% (n¼ 50/132) had seen
a GP. These women were most likely to have monitored their
symptom (53%, 69/132) and least likely to have visited A&E (3%,
4/132). Older women with frequent and/or severe symptoms
were significantly more likely to have seen a GP (38% vs 27%,
w2 (1, 397)¼ 5.11, Po0.05) but significantly less likely to have
asked a friend or relative for advice (16% vs 25%, w2 (1, 396)¼ 4.34,
Po0.05) than women who did not fall into this group
(see Table 4).
DISCUSSION
Just under half (44%) of the women in our sample reported a
symptom that may indicate a gynaecological cancer, and for a third
(35%), the symptom was frequent and/or severe. The rates of GP
consultation for potential gynaecological cancer symptoms found
here (13% of the women in our total sample, n¼ 120/911) are
somewhat lower than those reported by Stapley and Hamilton
(2011) (20%). However, analyses on a subsample of our participants
aged 16–29 (to allow a comparison with Stapley and Hamilton’s
(2011) sample) did show similar rates of consultation (21%; analyses
not shown here).
Interestingly, previous research exploring intention to seek help
for some of these symptoms in a UK population found that 65–
89% of women said that they would go to their GP within 2 weeks
if they had one of these symptoms (Target Ovarian Cancer, 2013).
Our survey suggests that, although just under half of UK
women may currently have a symptom potentially indicative
of a gynaecological cancer (n¼ 398/911), only around a third
Table 2. Gynaecological symptoms reported by all respondents (n¼ 911) and by age and frequency and severity
o45 years (n¼469) X45 years (n¼442) (n¼398)
Whole sample
(n¼911)
Frequent
and/
or severe
Not
frequent
or severe
Frequent
and/
or severe
Not
frequent
or severe
Chance of selection
over number of
endorsements
Symptoms endorsed n (%)a n (%)a n (%)a n (%)a n (%)a n (%)
Pain in abdomen/lower back/pelvis 173 (19) 81 (17) 27 (6) 55 (12) 10 (2) 64/173 (37)
Increased abdominal size 154 (17) 62 (13) 26 (6) 45 (10) 21 (5) 63/154 (41)
Increased need to go to the toilet 138 (15) 60 (13) 13 (3) 51 (12) 13 (3) 46/138 (33)
Increased wind or constipation 121 (13) 42 (9) 15 (3) 46 (10) 17 (4) 44/121 (36)
Difficulty eating/feeling full quickly 116 (13) 53 (11) 14 (3) 40 (9) 7 (2) 49/116 (42)
Heavier/longer periods 107 (12) 52 (11) 24 (5) 23 (5) 7 (2) 34/107 (32)
Pain/discomfort during sex 83 (9) 39 (8) 26 (6) 11 (3) 5 (1) 23/83 (28)
Itching, pain or soreness of vulva 64 (7) 24 (5) 17 (4) 18 (4) 4 (o1) 23/64 (36)
Bleeding between periods 49 (5) 17 (4) 20 (4) 7 (2) 4 (o1) 17/49 (35)
Discharge that smells unpleasant or is blood stained 44 (5) 22 (5) 15 (3) 7 (2) 1 (o1) 9/44 (20)
Bleeding during/after sex 31 (3) 10 (2) 13 (3) 1 (o1) 6 (1) 13/31 (42)
Growth/lump/sore/ulcer on skin of vulva 26 (3) 5 (1) 11 (2) 1 (o1) 8 (2) 11/26 (42)
Bleeding after menopause 10 (1) 1 (o1) 3 (o1) 0 (0) 6 (o1) 2/10 (20)
aRespondents were able to select more than one symptom, and hence the total percentage will exceed 100%.
Table 3. Symptoms reported by age group (n¼ 911)
Total
sample
(n¼911)
Women
aged
o45
(n¼469)
Women
aged X45
(n¼442)
n (%) n (%) n (%)
Did not report symptoms 513 (56) 235 (50) 278 (63)
Reported at least one symptom 398 (44) 234 (50) 164 (37)
At least one frequent and/or
severe symptom
317 (35) 186 (40) 132 (30)
No frequent or severe symptoms 78 (9) 46 (10) 32 (7)
Table 4. Help-seeking for one index symptom among respondents who
reported a symptom by risk group (n¼ 397)
Higher-
risk
women
(n¼132)
Lower-
risk
women
(n¼265)
Response to symptom n (%) n (%) v2 (df)
Monitored symptom 69 (53) 147 (55) 0.28 (1)
Used own remedy/self-treatment 59 (45) 104 (39) 1.08 (1)
Sought help from GP 50 (38) 71 (27) 5.11 (1)a
Sought help from internet 32 (25) 79 (30) 1.26 (1)
Sought help from friend or relative 21 (16) 67 (25) 4.34 (1)a
Sought help from pharmacist 21 (16) 33 (12) 0.90 (1)
Sought help from practice nurse 18 (14) 35 (13) 0.02 (1)
Sought help from somewhere else 14 (11) 30 (11) 0.05 (1)
Sought help from A&E 4 (3) 20 (8) 3.17 (1)
Higher risk¼women aged X45 years with a frequent and/or severe symptom. Lower
risk¼women aged o45 years and women with no frequent or severe symptoms.
aSignificant at the 0.05 level.
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(n¼ 120/398, 30%) have sought advice from a GP. This percentage
is considerably lower than the percentage of women who said that
they would seek help promptly for similar symptoms. This suggests
that actual help-seeking may be much lower than anticipated help-
seeking and adds weight to the evidence that intention may not be
translated into behaviour (Sheeran, 2002). This disparity between
intention and behaviour in help-seeking may be due to the
influences on help-seeking behaviour in response to an actual
symptom (Andersen et al, 2009) that participants may not consider
in a hypothetical situation.
Our findings suggest that many more women in the UK have
symptoms potentially indicative of a gynaecological cancer than
seek help for them. Any successful intervention that encourages
women with these symptoms to seek help at primary care level
could lead to a considerably increased pressure on the primary care
system. However, it may not be appropriate to encourage all
women with these symptoms to seek help immediately; for some
women, it may be advisable to monitor the symptom in the first
instance.
It is likely that the majority of symptomatic women in
the current sample did not have a gynaecological cancer, based
on the incidence rates for these cancers in the UK population. In
the highest-risk age groups for cervical cancer (30–34 and 35–39),
we would only expect one case in every 5650 and 6173 women,
respectively. In the highest-risk age groups for uterine, ovarian,
vulval and vaginal cancers (70–74, 80–84, 85þ and 85þ
respectively), we would only expect to see one case in every
1101, 1437, 4082 and 23 810 women in the UK, respectively
(Office for National Statistics, 2012b). These incidence rates mean
that, statistically, we would expect to find less than one case of a
gynaecological cancer in our sample of 911 women. Encouraging
all of the women in our sample to seek help then may not be
appropriate and an alternative course of action may be to target
higher-risk groups in any intervention aimed at encouraging
women with symptoms to seek help. However, encouraging all
women with a symptom they report as frequent and/or severe to
seek medical help (whether this symptom indicates cancer or a
more benign condition) is likely to be of benefit to the patient in
terms of receiving treatment and ameliorating discomfort.
Just over a third of the women in our study (35%) reported a
symptom potentially indicative of a gynaecological cancer that was
frequent and/or severe. As some of the symptoms explored in our
study are more likely to indicate a gynaecological cancer if they
have such characteristics (Olson et al, 2001; Goff et al, 2004),
women with these types of symptoms may be at a higher risk of
developing a gynaecological cancer. Furthermore, younger women
were more likely to report a symptom, whereas most symptoms are
more likely to be indicative of cancer in older women (Cancer
Research UK, 2012a,b; Office for National Statistics, 2012b). For
example, abdominal distension, loss of appetite, abdominal pain
and urinary frequency all have higher positive predictive values
(PPVs) for ovarian cancer in women aged X55, compared with
younger women (Rossing et al, 2010).
If interventions are not only targeted at women with a frequent
and/or severe symptom but also at those who are older, the
increase in consultations could be minimised. For example, our
data showed that only 14% of the women surveyed (n¼ 911) were
both older (X45 years) and had a frequent and/or severe
symptom, but 5% (n¼ 50/911) had already seen a GP, so around
9% (82/911) of our total sample could be characterised as needing
to see their GP urgently. Targeting interventions in this way should
ensure that consultations occurring as a result of encouraging
earlier help-seeking would be more likely to lead to a cancer
diagnosis. In terms of trying to increase early-stage diagnoses
of gynaecological cancers, this relatively modest increase in
consultations as a result of any successful intervention could
potentially be worthwhile.
Limitations. Over half (58%) of the women who completed the
overall omnibus survey did not agree to complete our questions,
which raises the issue of whether our results reflect the true prevalence
of possible gynaecological cancer symptoms in the population.
However, the final sample was broadly representative of the UK
female population in terms of ethnicity and SES (Ipsos MediaCT,
2009; Population, Ethnicity, Religion and Migration (PERM), 2009),
despite demographic differences between respondents and non-
respondents. Feedback from the interviewers indicated that the reason
women gave for refusing or withdrawing was often being embarrassed
by the survey content, despite the assured anonymity and the ability
to self-complete the survey, suggesting that the data may not be
missing at random. It would be difficult to overcome this limitation in
any self-report survey with similar content.
Because it is not clear whether embarrassment would be more or
less common in women with symptoms, we are unable to speculate
about the direction of any possible bias. However, to estimate the
impact of the missing data on our findings, we extrapolated the
number of women with at least one symptom from our sample
(n¼ 911) to a sample including our sample and the non-
responders (n¼ 2173), using the demographic information we
had for the non-responders (age, SES, ethnicity and marital status).
This showed that the number of women that we would expect to
report at least one symptom (based on the demographic structure
of the sample including the non-responders) ranged from 43% to
45%, very similar to the findings in our final sample (n¼ 911). Of
course, these estimations do not take into account alternative
reasons for non-response, such as having a symptom and feeling
too embarrassed to talk about it.
Because of the small numbers of women endorsing each
symptom, we analysed all the symptoms together, rather than
individually or by cancer type. This meant we did not report
findings on help-seeking for individual symptoms or by gynaeco-
logical cancer. However, any frequent or severe symptom would be
of concern, and it was therefore important to explore help-seeking
responses to all symptoms combined.
The exploration of help-seeking for only one randomly selected
index symptom was necessary to reduce the overall length of the
survey but may have meant that help-seeking was explored for a
symptom that was neither frequent nor severe, when that
participant may also have had a symptom that was either frequent,
severe or both. We ran an additional analysis (not reported here) to
explore how many women this applied to. Our analysis showed
that 62 women (7% of the total sample) had a mild, infrequent
index symptom and also a frequent and/or severe symptom for
which help-seeking was not explored.
We felt that it was important to explore the help-seeking behaviour
for all symptom types, including the seemingly less-serious
symptoms, as this helps to provide a picture of whether people seek
help appropriately. However, we acknowledge that it would have been
interesting to have had help-seeking data for all of the symptoms
endorsed. This could be a consideration for future research.
Finally, the survey did not go through any rigorous reliability
and validity testing. Wherever possible, the items drew on previous
published work. For example, the frequency and severity questions
are similar to those used in a previously published study exploring
ovarian cancer symptoms (Goff et al, 2004). However, future
studies using similar measurements may benefit from carrying out
psychometric testing before use.
CONCLUSIONS
There is a clear indication that the occurrence of gynaecological
symptoms potentially indicative of cancer in women in the UK is
substantially higher than recorded in primary care. Our findings
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suggest that the most likely alternative to help-seeking may be to
monitor the symptom. However, it may not be appropriate to
encourage all women with symptoms to seek help at the primary
care level immediately.
Older women were less likely to report a symptom than younger
women. Evidence that symptoms are more likely to be indicative of a
gynaecological cancer if frequent and/or severe, and that gynaeco-
logical cancers are more common at older ages, suggests that
targeting interventions towards older women who have a symptom
that is frequent or severe could promote appropriate help-seeking
without increasing consultations with the ‘worried well’.
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